Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line
- PMID: 7718264
- DOI: 10.3109/02841869509093963
Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line
Abstract
The 4-hydroperoxycyclophosphamide (4HC)-resistant B5-180(3) subline of the cloned KBM-7/B5 cell line was developed as a model of induced cyclophosphamide resistance in human myeloid leukemia. Based on IC90 values, this subline was approximately 20-fold resistant to 4HC. Furthermore, it was significantly cross-resistant to phosphorodiamidic mustard (PM), whose cytotoxicity is independent of aldehyde dehydrogenase (ADH). Using alkaline elution we found that the resistant line had decreased initial levels of DNA interstrand cross-links (ISCs) following 4HC but not PM treatment. The resistant cells also appeared to remove ISCs from their DNA more rapidly than the parental cells. Our data therefore suggest that 4HC resistance in the B5-180(3) subline is multifactorial; ADH is an important mediator of its resistance to ISC induction by 4HC, while a second process, which may involve an increased ability to tolerate drug-induced DNA damage, appears to be important for its resistance to both 4HC and PM. The B5-180(3) cells were also cross-resistant to gamma-radiation (approximately 1.7-fold at a surviving fraction of 0.1); if generally applicable, such effects could have important clinical implications, since pretransplant total body irradiation is a major component of the eradication of leukemic cells.
Similar articles
-
The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues.Cancer Res. 1994 Oct 15;54(20):5394-400. Cancer Res. 1994. PMID: 7923171
-
Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs.Cancer Chemother Pharmacol. 1996;38(5):406-16. doi: 10.1007/s002800050504. Cancer Chemother Pharmacol. 1996. PMID: 8765433
-
Development and characterization of a cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis x Brown Norway hybrid rat.Blood. 1990 Sep 15;76(6):1209-13. Blood. 1990. PMID: 2400809
-
Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s).Cancer Treat Res. 2002;112:161-75. doi: 10.1007/978-1-4615-1173-1_8. Cancer Treat Res. 2002. PMID: 12481716 Review. No abstract available.
-
Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines.Cancer Treat Res. 2002;112:199-209. doi: 10.1007/978-1-4615-1173-1_10. Cancer Treat Res. 2002. PMID: 12481718 Review. No abstract available.
Cited by
-
Cyclophosphamides as hypoxia-activated diffusible cytotoxins: a theoretical study.J Comput Aided Mol Des. 2000 May;14(4):307-16. doi: 10.1023/a:1008128023564. J Comput Aided Mol Des. 2000. PMID: 10815768
-
Identification of potential genes associated with ALDH1A1 overexpression and cyclophosphamide resistance in chronic myelogenous leukemia using network analysis.Med Oncol. 2021 Sep 7;38(10):123. doi: 10.1007/s12032-021-01569-9. Med Oncol. 2021. PMID: 34491453
-
SIRT1 as a potential key regulator for mediating apoptosis in oropharyngeal cancer using cyclophosphamide and all-trans retinoic acid.Sci Rep. 2024 Jan 2;14(1):41. doi: 10.1038/s41598-023-50478-6. Sci Rep. 2024. PMID: 38167952 Free PMC article.
-
Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.Haematologica. 2017 Jun;102(6):1054-1065. doi: 10.3324/haematol.2016.159053. Epub 2017 Mar 9. Haematologica. 2017. PMID: 28280079 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical